Progressive hemifacial atrophy, AQP4-positive NMOSD and suspected Sj&#246;gren&#39;s syndrome: five-year relapse-free follow-up during rituximab therapy.

Rituxan (rituximab) - Roche

Progressive hemifacial atrophy, AQP4-positive NMOSD and suspected Sjögren's syndrome: five-year relapse-free follow-up during rituximab therapy. (PubMed, Acta Neurol Belg) - Oct 21, 2026 - No abstract available
Journal • Immunology • Neuromyelitis Optica Spectrum Disorder • Sjogren's Syndrome

http://www.ncbi.nlm.nih.gov/pubmed/42902068

Shilin Yang; Siyuan Song; Xiaochao Feng; Yan Liu

Oct 21, 2026